Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
Adult
Aged
B-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cell Communication
/ immunology
Chemoradiotherapy, Adjuvant
Cohort Studies
Disease Progression
Female
Humans
Kaplan-Meier Estimate
Lymphocyte Activation
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Neck Dissection
Oropharyngeal Neoplasms
/ immunology
Oropharynx
/ pathology
Papillomaviridae
/ immunology
Papillomavirus Infections
/ immunology
Patient Selection
Prognosis
Squamous Cell Carcinoma of Head and Neck
/ immunology
Treatment Outcome
Tumor Microenvironment
/ immunology
HNSCC
HPV
Tumor-infiltrating B lymphocytes
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
17 10 2019
17 10 2019
Historique:
received:
15
05
2019
accepted:
30
08
2019
entrez:
19
10
2019
pubmed:
19
10
2019
medline:
4
8
2020
Statut:
epublish
Résumé
Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rates in OPSCC patients. Therefore, a better stratification of patients and the development of novel therapeutic protocols are crucially needed. The importance of tumor-infiltrating B cells (TIL-Bs) in shaping antitumor immunity remains unclear; therefore, we analyzed frequency, phenotype, prognostic value and possible roles of TIL-Bs in OPSCC. We utilized transcriptomic analysis of immune response-related genes in 18 OPSCC samples with respect to human papillomavirus (HPV) status. The density and localization of CD20 We observed significantly higher expression of B cell-related genes and higher densities of CD20 Our results indicate that high abundance of TIL-Bs and high density of direct B cell/CD8
Sections du résumé
BACKGROUND
Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rates in OPSCC patients. Therefore, a better stratification of patients and the development of novel therapeutic protocols are crucially needed. The importance of tumor-infiltrating B cells (TIL-Bs) in shaping antitumor immunity remains unclear; therefore, we analyzed frequency, phenotype, prognostic value and possible roles of TIL-Bs in OPSCC.
METHODS
We utilized transcriptomic analysis of immune response-related genes in 18 OPSCC samples with respect to human papillomavirus (HPV) status. The density and localization of CD20
RESULTS
We observed significantly higher expression of B cell-related genes and higher densities of CD20
CONCLUSIONS
Our results indicate that high abundance of TIL-Bs and high density of direct B cell/CD8
Identifiants
pubmed: 31623665
doi: 10.1186/s40425-019-0726-6
pii: 10.1186/s40425-019-0726-6
pmc: PMC6796441
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
261Références
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Exp Med. 2008 Jul 7;205(7):1635-46
pubmed: 18591411
Cancer. 2008 Sep 15;113(6):1387-95
pubmed: 18671239
Cancer Immunol Res. 2017 Oct;5(10):898-907
pubmed: 28848053
Trends Cancer. 2016 Dec;2(12):747-757
pubmed: 28626801
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Oral Oncol. 2016 Feb;53:27-35
pubmed: 26631955
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
Clin Cancer Res. 2013 Nov 1;19(21):5994-6005
pubmed: 24056784
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Cell Mol Immunol. 2017 Aug;14(8):662-674
pubmed: 28626234
J Clin Invest. 2010 Jan;120(1):168-78
pubmed: 19955658
PLoS One. 2012;7(6):e38711
pubmed: 22701698
Cancer Immunol Res. 2018 Mar;6(3):295-304
pubmed: 29378694
Oral Oncol. 2018 Jul;82:75-82
pubmed: 29909905
Blood. 2011 Jan 13;117(2):530-41
pubmed: 20962324
J Immunol. 2007 Mar 1;178(5):2844-52
pubmed: 17312128
Neoplasia. 2011 Oct;13(10):947-60
pubmed: 22028620
J Clin Invest. 1997 Dec 15;100(12):3173-83
pubmed: 9399965
Prev Med. 2011 Oct;53 Suppl 1:S5-S11
pubmed: 21962471
Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1137-46
pubmed: 19917928
Nature. 2016 Nov 17;539(7629):437-442
pubmed: 27642729
Scand J Immunol. 2004 Dec;60(6):543-51
pubmed: 15584965
J Invest Dermatol. 1999 May;112(5):716-22
pubmed: 10233762
J Immunol. 2010 Nov 1;185(9):4977-82
pubmed: 20962266
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Breast Cancer Res Treat. 2012 Apr;132(2):545-53
pubmed: 21671016
Front Immunol. 2018 May 30;9:1209
pubmed: 29899747
Curr Opin Virol. 2017 Feb;22:77-88
pubmed: 28086150
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
APMIS. 2010 Jun;118(6-7):510-9
pubmed: 20553531
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Oncoimmunology. 2019 Jan 10;8(3):1535293
pubmed: 30723574
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Gut. 2017 Feb;66(2):342-351
pubmed: 26669617
J Immunol. 2010 Apr 1;184(7):4006-16
pubmed: 20194720
Nature. 1998 Jun 4;393(6684):413-4
pubmed: 9623994
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
J Clin Oncol. 2017 May 10;35(14):1542-1549
pubmed: 28328302
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Oncotarget. 2016 Aug 30;7(35):56781-56797
pubmed: 27462861
Annu Rev Immunol. 2005;23:23-68
pubmed: 15771565
Anticancer Res. 2006 May-Jun;26(3A):1827-31
pubmed: 16827114
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348